SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is actively trending, with its community demonstrating strong conviction and calling to 'hold' amidst current market volatility, anticipating a significant breakout. Many perceive it as 'digital silver' poised for substantial long-term growth, with discussions highlighting its foundational role and developments like LitVM and Omnichain features for earning yield.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

Ongoing CME margin hikes and impending Chinese export restrictions are driving significant volatility and intense debate around SLV. The community is sharply divided between those anticipating a continued silver squeeze fueled by industrial demand and those fearing market manipulation and a potential sharp pullback in the highly contested paper market.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as investors anticipate a potential rebound with the close of year-end tax loss selling, coupled with ongoing speculation about Elon Musk's future actions regarding X payments. The community shows a strong divide, with many asserting its status as the 'King meme coin' and envisioning significant price appreciation, while others express skepticism about its immediate trajectory.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for NEREUS, its motion sickness drug, marking the first new medication in this category in nearly 40 years. The community is highly optimistic, anticipating its significant potential to address GLP-1 associated nausea and sparking strong speculation of a major pharmaceutical buyout. With several additional pipeline catalysts on the horizon, many view the stock as deeply undervalued and poised for substantial future upside.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending due to its exceptionally active and dedicated community, which passionately advocates for the "OG meme" narrative of Rage Comics. This committed base is consistently building out an ecosystem with projects like RageMaker and RageGames, aiming to onboard new users into crypto while expressing strong conviction for significant long-term growth and widespread recognition, often positioning themselves against other meme coins for the top trending spot.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics is surging with immense trading volume following news of a proposed business combination with Applied Digital's cloud division, forming an AI compute platform called ChronoScale. This pivot into AI infrastructure, combined with the stock's low float, is driving aggressive price action and high price targets among community members. However, some discussions highlight potential significant dilution for existing shareholders, creating a divided outlook on its long-term implications amidst the short-term volatility.

Function is building the financial infrastructure that makes Bitcoin productive, unlocking yield, liquidity, and capital efficiency for holders across DeFi and traditional finance. FBTC turns Bitcoin into an asset that works.  FBTC represents the first omnichain Bitcoin yield asset, enabling BTC holders to participate in structured, risk-managed and programmatic yield strategies. FBTC is fully backed on a 1:1 basis with BTC, Bitcoin Reserve Address List is public and can be verified at any time. FBTC combines the security of Bitcoin reserves with the flexibility of smart contracts, creating a secure and efficient bridge between the Bitcoin network and modern DeFi protocols.  FBTC turns idle BTC into a functional and productive asset. The primary purpose of FBTC is to bring native Bitcoin liquidity into DeFi. Enabling Bitcoin holders to access a wide range of yield generating strategies, without having to sell their BTC. This not only enhances the utility of BTC but also allows holders to earn returns on their assets, making FBTC a powerful tool for maximizing the potential of Bitcoin in the DeFi ecosystem

Function ƒBTC

FBTC is trending amid ongoing volatility in the Bitcoin ETF market, characterized by recent outflows followed by a modest reversal of inflows. The community remains sharply divided, with some anticipating a prolonged "crypto winter" and further declines, while others maintain a bullish long-term outlook, emphasizing Bitcoin's historical resilience against market fluctuations.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind Corp is actively discussed following the FDA's recent approval of FUROSCIX for pediatric use and new patents for its ReadyFlow Autoinjector, with a key PDUFA date for the autoinjector set for July 26, 2026. While many anticipate significant revenue growth from these developments and Afrezza's international expansion, a vocal segment of the community remains highly skeptical, citing past commercialization challenges and expressing strong dissatisfaction with current leadership.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull (BULL) is trending due to significant year-end tax loss harvesting and persistent selling pressure from initial SPAC investors, which continues to drive down its share price. The community is sharply divided; bulls emphasize the company's profitability and international growth potential as a long-term accumulation opportunity, drawing comparisons to early fintech successes. Conversely, bears highlight ongoing dilution and concerns over the stock's performance, questioning its fundamental value.

Featured in Matt Furies latest book Cortex Vortex as Ratos nemesis. The character is also part of ZOGZ which confirms its real name.  Matt Furie, the artist best known for creating Pepe the Frog, has been working on a new book. The news comes from his editor, who goes by the handle @beuys_on_sale_ on Instagram. In a recent post, the editor hinted at an upcoming project featuring new characters named Gasspas and Rato. Gasspas’s visual appearance can be inferred from the artwork. In one illustration, Gasspas is depicted looming over two rats (Rato and Wat), gazing down at them in a menacing way (an image that has circulated among collectors). This inferred that Gasspas is Ratos nemesis in the new book Cortex Vortex reinforced by community quips that “cats eat rats”. Gasspas debuted as part of ZOGZ, a collection of 111 original NFT character illustrations by Matt Furie launched in May 2023.

Gasspas

Gasspas ($GASS) is trending amidst active community discussion, fueled by recent visibility on Dextools and strong 'HODL' sentiment. Many investors are captivated by its potential for significant growth, often drawing parallels to $PEPE due to shared creator involvement, while others vocalize skepticism and concerns about its trajectory. The project also garnered attention for recent charitable donations to a cat adoption center, reinforcing its community-centric meme coin identity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company said that the planned confirmation late-stage trial is designed to demonstrate the efficacy of Lacutamab in certain patients with Sézary syndrome and Mycosis fungoides.</li><li>The primary goal of the study is to gauge progression-free survival.&nbsp;</li><li>The FDA reviewed the protocol of the trial with no further comments, the company further noted.&nbsp; &nbsp;</li></ul>Shares of Innate Pharma SA (IPHA) soared 13% in the premarket session on Monday after the company said that the U.S. Food and Drug Administration had cleared a confirmatory late-stage trial of Lacutamab in cutaneous T-cell lymphomas to proceed.Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma that affects the skin. Symptoms include patches, plaques, or tumors on the skin that can be itchy and may resemble eczema or psoriasis.<h2 class="st-heading-2">About the Late-Stage Confirmatory Trial</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251109757297/en/Innate-Pharma-Announces-FDA-Clearance-to-Proceed-With-TELLOMAK-3-a-Confirmatory-Phase-3-Trial-of-Lacutamab-in-CTCL">said</a> that the planned confirmation late-stage trial is designed to demonstrate the efficacy of Lacutamab in patients with Sézary syndrome and Mycosis fungoides, who failed at least one prior line of systemic therapy. Both Sézary syndrome and Mycosis fungoides are types of cutaneous T-cell lymphomas.The primary goal of the study is to gauge progression-free survival or the length of time a patient lives with a disease, such as cancer, without it getting worse, which can include time when the cancer is stable or cured.The company now intends to initiate the confirmatory trial in the first half of 2026. The FDA reviewed the protocol of the trial with no further comments, the company further noted.In a mid-stage trial, Lacutamab demonstrated durable activity, a favorable safety profile, and improvements in patients’ quality of life.“...this milestone brings us one step closer to our next goal, submitting for accelerated approval in Sézary syndrome once the Phase 3 trial is underway,” CEO Jonathan Dickinson said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IPHA">IPHA stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:623/63;" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAm8AAAA/CAYAAAC2Jy9WAAAQAElEQVR4AeydC1RU173/v4eHMwjCgIKMkchUY8TYNObRGNo8pP/4v0K5NWhesGJWRGkU41qJJr3tMlldqe1dbTVtY0CrYlbsxWiikoYr9porXpdX0TRqczVAfNzBiM4ElEEFZkYGuPt3hhlmhnkCDo/5zTp7zjl7//Zv7/OZM19+Z+9zhrAufjEBJsAEmAATYAJMgAkMGwJh4BcTYAJMgAkwgT4R4EpMgAkMBgEO3gaDOrfJBJgAE2ACTIAJMIE+EuDgrY/guNrQIsC9YQJMgAkwASYQKgQ4eAuVT5qPkwkwASbABJgAE3BHYNjleQ3ebt1qR3PzTTQ0NOHKlUZOzIDPAT4HBuUcIA0iLSJNGmiVJZ/km9pgnWOd53OAz4HBOgdIg0iLSJN86ZzH4I0cGAw3EBERgfj4WKjV4zBhQiInZsDnAJ8DQT0HSHtIg0iLSJNIm3wJm7/l5It8km9qg9oaVJ3jcyuo5xZ/1vw3faicA6Q9pEGkRaRJpE3edCzMXeG1a9fl7KSkBMTERCEyMgKSJMl5/MYEmAATCCYBSZJkDSItIk2itm0aRdt9TTYf5JN8s871lSTXYwJMoL8EJCkwnesVvFG0Fx4eBpVqDAds/f00hm997jkTGJIEJEmStYk0irSqr52kuuSDda6vBLkeE2ACt4uAJPnWOafgjeZZzeZbiIuLuV19Yr9MgAkwgX4TII0irSLNCtQZ1aG65CPQumzPBJiAPwTYZiAIkEaRVpFmufpzCt7a2kyIjh7NI26ulHifCTCBIUVAkiRZq0izAu0Y1WGdC5Qa2zMBJhBsApLkWeecgjeK7hSKyGD3j9tjAkyACQRMgLSKNMtbRXdlVIfquivjPCbABJjAUCJAWkWa5donp+DNYulARES4qw3vMwEmwASGHAHSKtKsQDtGdahuoPXYngkwASYQbAKkVaRZru06BW9UKEn8VClxGNjE3pgAExhoApLUd62SpL7XHejjYH9MgAkwAU8EJMm9VvUK3jw54HwmwASYABNgAkxgEAhwk0zAhQAHby5AeJcJMAEmwASYABNgAkOZwNAO3m7oobsxlPFx35hASBHggx3RBOpxtOwYLo3oY+SDYwIjg0D/g7dOPY7u2Iz16yltwNay02jq7COcxmMo3XvWXvn84TLsOnzBvn+7Nmr37sTRxtvlnf0yASYw3Ak0HNmJ4s37UeuobRcPYevGoakdli/LUVxe7YT9+vFd+OCg3inPeceAK3V6NDln8h4TYAJDkEC/gzfdf+3HGdUcvPLKEpEK8OT00VD01WuTAU1Gsx3TlKyleCVrsn3fvjGgGzfQdM0Mk2VAnbIzJjBsCHR1AUbxvbt5sw0Gw01cvdqMhoYm6PXXoNM1inQV3357DY2NBtC/lLp+vQUtLUa4e3x92Bx0gB3tMJsR0VWPM6d7Ktb+z0WYYB6S2hExVY24uouotXf3Br762oAkTbI9hzeYQCgRGGk619cwy/6Zm271BFtAOFLunozo7tLW84ewY/NmFBdvxlYxotZK+TS6Vv4FzuzdhuL33sMf6GrWKAoo/7MLsFz+bxR3X83S1W7pEeuQGG2XHzmNT94XI3x/2ozSo/W4dHgXthYLHxvL8aXsXPjpNODLMuF7o2h30y4cvSzyxEKja5X/OCL3Z71c33oFSvknDELYyoS96KMw5YUJjHgC7e0W3LjRKgdkt27dwvXrN3HzZqsI4kxyUEaPpnd2doIEr0u8dXR0gurQr323thpF3RbQmoI5g/j+UPBHdiMZXERsLJrOnbYeYudZ1DbEImm0dVd+b72Ayh1bhX4JLSnZh9puTdId2YVNQgOLN27FjsP1oOtEd3lN/9iHD0gv39uA9dsOQWcb5bt8TNatYtI0Oe20zhR4aE/uS9RUaOLqoa2T90R0fhba6xOhSRX7No2kPhVvQ3lNm8h0WUiP/+0YGrqzSX9LB0iLu10O6oobDw0CpFkjVef6HbxpHn0c6m/KRRD2CSpPN8rCJJ8WTcewa78BablLsGzZInz/1iFUfi1KLGaY675G0715WLZ8OeYmXcDxkzeAxFnIe3QicMcPsezlZ5GeCNDVrtncISpZt+sumvHYi2KE74XpsBwvx/Exc7Bo2XJkp+hx4nNrkFe7dxdOxM0RPkS7T6lx7sAxXBcezMZG1F6Mx9z87vonTslXpdOysnFPTCzueUrYZ00VlrwwgZFLgIKypqYbctDW0tLWHZC1Q6EYFfBBjxo1ChTMUeBGARyN1rWKwE7EegH7GhYVkiZDY/gaJ+hi82uhYXdMREK7recGHN1diaa052TtKZhlQWUl3QJSjeNfAA+/LPTl5UVYMGsiIuAuD1CoZ2Ke0Kdly5fiybhq7K8SuohGVP6tGmPnUP0lmJOiQMr/e1boo6f2bP2JxT2TR+PS2Xo5w3z6AppSJ2Oa2KvduwMnhHYuWyZ8vjgTrQfKcNR1rpR0Wow2WtXXqr8DpcWiC7wwgdtKIBR0rt/BG6KnIrtgKV58LBFNx3ZiffdImvn8RdwQV6qWr0/hxMn/gXmUAo2XraNdGD0Rd6WEg15xY6JFkObmyo8KXVJ0shBL6nFCLKKhxl33xcoW0VEKoItk5iK0l8ORoNSJNkW7lyxQtOhRB+srKXU64mz1SZys2fzOBAaJQPCa7ejoEFOiN+TpUJPJcbQccgDWl+AtjL5LDodAo3M0pUpBHAV0DkUjZFONGZPbcO6rNtSeNSAlTVxs2o7MeEGMbMUirkMEdydP4UtjBJQNOuiQCs0dBhzfdQhndGZEREK83OUB0eMT0VF3CpV7y/GPqxQwkS6SrimgGCOqiSU83IwbTeLz89ieMOpe4tJSobh0QfQBqP2mCalT6eKUNDIaqd/rnj6N/i7um3QD2vPCZ3c9f1b91WJ/2mAbJhAogVDSORf5DRSVzV4ETHf/AAuWLEJ69FmcOG2GSUzL2Erltfq7+P7d8fLm7Xszw9Lu6D0Wd82aiRTHLN5mAiFGgKZDv/22SUyJuv8DTVMLkZERAVGJiAgX06s0Adi7mk1A6d45ugLubTF8c9T3TYb57H6cuT4JMyY5HIfZ0jPrQNlhyfjerLuRgNH43gIx4vZgNLT7t6G4rBpmt3liJO3ftmLfeQXuenQOHtdEkxeRkvHwTAW+3L0Tn5TtxMGGqch4UCEibk/tiSq2JWGy0L56aJtO45w+FXfdTQWkkeFQRtJ2T7K0uz83eiwC3aJ2HOuwFjvS4O2BJxBqOicHb33H2Ibaw1/gklPABDEFo0DcRDUUbRYk3DcTD9wvkljPuEMBn69OnxZeDCZhQmIbWiPutrYptztJCKiXKnKRBR39ald2wm9MYEgRoMCJHjKgBxF8dYwCrvBw/+VAIaZZacrUm99bt9rl6VmaSvVmN6zKEqZD016PVs29UDt2XDURExStsCQIrSPdoZSWDAU6xAVlOBK+8yCyX5yFpG8u4JzbvHpcMSTjgTnTkRKrQKvRFkzdwJfVHXhg/jzM/tE8LFr4ONT0MXlsz7FTyUjTdEBbeQENKdYpU2CS0EgDtGfbrIadF6HVKTBhonUWw5op3seLsLPFgAZZF9vQcLVVZAayUDt90eJA2mBbJgCEqs6RDPTj8x+NpDE67Nu4wXqT7nsf4MSoHyDje8LlpAxk32PAvuJtKBVXjPIj9ddEvrdl6lRoGg5h/UZxBUr3x3mzdVumwAPZcxD75Qco3vYJdm3bik17z8Img26rQAjcdyJwZs9mFO84xo/Ju4fEucOMAAVOV68a5Hva/Om62RzYfW+RkZGyaPryTQ8x0FRqc/NNX6bDpDwejz23EAtmxbv0dyKezJqOpr9twNbt5Sgt2YzSYwag8RR2vb8VH+yivGNovfchzHCXh4nQJOrxWclOlH5Qihrj6G7/sUhJasXx7UJHRSp+fyfKD19Aq7B32x6cX+rJE9F6SYcJQlutJY4aWYqtxfvRdE8mnpRHEeMRF12PE4f1QNhUzLhTh0p6qGFjGRqiE6zV3b+7yXVsx18tduOGs5iAFwKhrHP9DN4gRtayUfDKUuTnPosXf7oUyxbMtI90qX/wLJYtexY/pitGsU4fKz4F9eNYlC+uHsUmLeqMhViU0X3/RdR0zFu+FAUvLcJcMcTvWOa4DXwXC16dB4oRe/mge/CWCB/zMzD3+UUoyJ4qrn4hpi6WY4Gtgmv92QvxasFCFDw3y9538suJCQxHAnS/GU1ZdnZ2+d19s/mWGDH3/6GFri55SMZv/21tJvlnRrqG6dMMTvqjiEW0PO2YjIz8hciwDcHdMQt5Ly9F3o8fx4KXliAvXQR4iQ/iuYJFyJv7OOYtXIIXZycD7vIQjweeW4KCp+diwQt5yF6QZ9XFzrP4x+WJmEcPF7wsyp+ZBeXZIziuE+jdtSeynRZxEV3w6lLMS3PItWtkNvKE37wfiD7JxSIAXbwUC+V9BWY8JfR84bPIL8gTgemz1v4IOycWrlrqqOf2djKctFi44IUJ9JtAqOtcWL8JdjtQxNoErTvDtgpTIE5MA8DvV7j4I4J+vyKiPfTHk2eFAoHd9ePJEecPGgFuWP75DnryM1AU9LCBQhGJuLgYxMfHYtw4FZKSEqBWj5MTbVMelalUY0DTrIG2QQEi/bTIcA3g/D1e0kJFmLO1Oz1yl9errrlVTKG2oamZHlwAOm7o0NARjyRVj/9edXqKvG5R+679RFg4Ihz63lffjg1TO9Zg1zGXt5lA3wnQrRihrnMOX9O+g+SaTIAJDD4BGt2iKcpAejJ6tFIO1ChICwsLQ3R0FKKiFBg1KhL0UIIkSZAkSd6mPCqjOrGxMUhMjEdMzGiEh4f53SRNc1AA53eFUDeMmokF8yeh4VAFPikrx74vI8S0bTZmRIU6GD7+UCVwO3WONG+46Jz/qhuqZwofNxMYBgTopt1AAjd64GD8+ASoxCgaiVVfDjEyMgKxsdEYP36sWMfIQR78eFEARz+c6YcpmwgCEeNnYu5T2ZhH6Z8eREqsyOSFCYQgAda5ng+dg7ceFrzFBIYlAZqGbGq6Dlr7OoAwMboWHz8GY8fGiRGzcF/mfpfHxESJadZ4UFDoTyX6gWCaRvXHNvRs+IiZABNwJUD6xjrXQyWsZ5O3mAATGI4EaMSNrkh99T0iIlye6oyKUvoy7VN5eHi4HBTS1Ks/DgyGm6B77fyxZRsmwARCmwDrnPPnz8GbMw/ecyDAm0OfQGdnJ0ymWz47SlOjdI9aePjt/8rTQw/+BHDUd6PR5LPvbMAEmEBoEyCtYJ1zPgduv5I7t8d7TIAJDCABGnEbPz5BftDAk1sK3GiaVJIkTyYDnu8rgIuIiBCjdCq0Se2ov351wNtnh0yACQw6gQHrAOtcb5QcvPVmwjlMYFgQoH9rRb/nRomeAqWf86BAzbHzNNKWkBDn98MEjnX7u00BnOs9cGFhkvxzJDHxo7H+eDke3/gGfnNwZ3+b4vpMgAmMUAKs1vaDogAAEABJREFUc+4/2P4Hb6Zm6PV6l9QMk8V9g0MztxKrUtRQv1YZWPdcjr25JbDqqCtClmg3a4NWrqjdkAV1ShaK6mjXhIoVasSnrEKVV5Z97Ds1wWlYE7D92yubuNH/9qPfYUtIiLU/jED7FDAN1oFSX+heO2qfplITkxLwN+1JZGz6FxRX/TvMlnb8x9cnoW3Sk8ntSQPh1eW7btW80NK5ZpMjSBOaSfdtmeeLkB4fj6z3/fgcXXTP0StvMwFXAqxzrkSs+/0P3j4rhFotAh+nlN4dgFgbcfdesVCCtLDCXdEg5JmgqxcB6FUndfLdD5djjx8jjillPkpqfVeVLSwmaEW7WlvQ16KFvl7bE/iK7ohFNvX81se+e3bIJcOAAE0jmExmp54ajWY0NDShvb0DiYkqMS0ZJ/9em5NRkHckSUKCGPlLSoqHtrUBT/1lDV7fW4KGluv2nnShCxuODRUtsHfLecPlu27VvNDSucLPHJFUopA0f0VlT6bJt1rJxq66J2fyGxPoTYB1rjcTW07/g7duTznbdNDpbOkoClO7C9yu9CJYclswLDPtx356CzKv7sHiZSXQ9z6SAHOUyNykg/HSWjwSEWBVH+a//OUv8cwzz/iw4uKhTIB+qNJd/+hxehqBa2w0BBy41dfX47HHHpOnWMPDw/Hzn/9cBILtcjMtLS144okn5DJJEhcpItE+5csGXt5o5G3LF/uRIwK3M3p5WLmXdXnNcbS1OwejvYyGQIb9uy5rXWjpnFf8Uwpx1GjE3peSvZr1tZA1q6/khne9YOucjZbFYsHSpUtlvfvtb39ry/a6DrbODVjwplQlIznZllRQWqqw+iE11HOKIE8Kiv1VaWrc/8Z2/DFzJpYfBPBhnpgmVMM6bWid/lteXoN1j0YJaNOx7rywuVqBVTNpn/5gCNvNNSKTFqv94s2VWJepFvaiXJ0lRr302L6wez8yHescR8E8+iJ/tqRFUYbod45DANayB4tpenOz3mbktLYf+4z5yJktim42wyhWgLWP1uOjDOFb9FWd2c2EsrykytdEP8S0qfXathlVb6UjSvzRlCRxrK4jfJZTKBK+JUmUuR63SxskhNOnT+cAzoXLcNr1JGq2YyAhkSTJtutzTWL1+uuv4/Llyzh27Bj++te/4s9//jNKSkrkuq2trbh06RJyc3Px8ccfy4nOI6VSKZf7epuRPMmrCU2f/ue5U15thkKh/bsua11o6ZxX/q5ToZYalOR067A4D+OFfqpF6tFC4a1RaHua1K3di1HRLPI8LHSusWZ5gDOCs4OtczaUBw8exF/+8hcoFApbll/rYOrcgAVv2sN7sOdja6qsNQHKR7D67SyYPluO5R82Q79hpQikpqNwRQ7+/6urkUMXaLPyUfROEVbOVgswJjEap0fRP09HkXoNSj8qRV7qKREAZmFdSx52n9ahems6jhakY9UxiJfVvqRgPioeXIfdv8uBSl+BxWkarFGuxu5thZhpqcIqESyK3gAiuFn9UJYHX8KdfdFg/lMa6MtKsLvemmkqL0FJvQaZc6nT1jzHd9uxF72WiVX7VMh5LQ8a2cDaR/u0qMgzXdJDf0nukdjzvpiuCtt6HWTr8yXI/1UV0t+tFiOc1di7IgMax+58uBZ7iIPtuH2M/rEYemc/lEvpPxTQo/Pe+hgTE+2tuFfZtWvX8PnnnyM/Px8PP/wwsrKy8JOf/AQ7duwAja5RexTg3XvvvViwYIGcnnjiCdBTo72cucn4Yeo9mJGc6qakJ+vfaz7v2RmiW7bvOmldqOocHfuejyutF+W2z8nifAtIjdD+xWXT8d45I4zn3sP99XrEz13TrfXWSjW/X4fmFbu7tbsE89+qshZ4eGfN8gBmhGYPhs4RyoaGBrz66quyxo0bN46y/E7B1LkBC96qfj8f85+xpuXlOvlglXPXouR5JSp+kYHMN6qQ9rstyJ+oRNqTmbifmGgykPN0DjKmKWV7+W3Wezj60UrkPj0TyZ8V4dd1QO7ba5Au7OPnFiI/tRkVh+WxPNkcL5TiwNu5yHl9DVZNE1kz1mDvpkLkvLASeTPEvlZM5YoV/PFFdiIlv7QcOahCaRmNtJlEUFoBzM7H/Imi0M1StbkQha8VYs2GKjRHiGOp18LLRST689LVaGGISUPm64XIcPjn1HYOL6zFqmzRQmMzjGLlbWEx9EZn6Jb5+r2j8PAwccUYGdABhItpUhpFu3Lliv0/NSQlJUGr1eLmzZugf0RPqbq6GgUFBfjVr36Fq1evBtTGs/c+6tX+yMVqdHZ1ebUZ7MKQ1jkHjZ//zDp4C7W0dUKjZ2Qic4oSyiliLbS4RlzSOmp92u8OYMvSHKHdq1GYDJiaDT4/XtYsn4hGjMFg6BzddrJ+/XpZ75YtW2Z/8CsQqMHSubBAOuXNNvfTLln06eCrX7eOOwFiFGpFIVR1p3DKko/3XrXlw/PrLg3E91gu1545Kq+354rpQ7o5Vv0jrBPBnJzZ602IRESvTHtGQL5iclG4VImqTaXQWiqxtwzIeD7L3i+70+6NXLrf75IIEo1dqH47HnveyMPaM92FA7WashK7N+XAsDkL08dIUOeUoMbtU6hKqFTg1wgm0N7u9oO3H/Ho0Ur7tr8bY8eOxZNPPokNGzbg6aefxhNiVO0Pf/iDvbrZbMaECRMQFxeHO++8E2vXrpVt6CoVfr5+nPZ9hEueJcfYfgsXrlkv/Px0GXSzkNY5B43v6tqLXC/07380AzhTgqKDWmgPFqFE6GHO7HQPNVSIFxfnHgo5O0QJDIbOfS5mHzZu3Ai6zy0lJaVP5IOlc56VtE/ddq2kR8kv1sE0OwNplhL82p/HyB1caKbNFHtKFFb2BIY9waEoCmAJ1FdGbj6UQnz2vF+BPchE/vPJfrWWJkRLKSYUxICF3d5gGJhxuLQlu6EzGlH9US6iyhYj6+0aext92aCrWBpJ+eijj/pSnesMEoH29navLSsUo7yWuyuUJAnr1q3Dp59+Kgdpb7zxBt588015WjQsLAyTJ0+Wp1XfffddrF69GsXFxfjqq69w4sQJd+7c5sUpozF9/J1uy2yZX3170bY5jNahp3O+PpzkpwuRozRgz7J0pC87hfSt1Sh9PvCLCtd2WLNciYzc/WDrnFH8bf3Zz34mAy0rK8OqVatAPwlE9/ja7v2FH69g6dyABW+O94LQPRGn6oHmD/Ox+GAa1mw6gJJXVKgsyMd2WxxD3+OPS7G9To/mFg9EZuchX2VCUcFi7DmjFyC1OOV6r4WHqr2y/fFlaobtZ4vww0KsTK3B6hUlMGXnISeml0d7hqm5u2/7irD4pSKYxKRr1mwqjke8OE59eSkq67SofCsPq85QvksSwZ3j7+IZmk0uBmK3tgSrfl8JvUmJNAqGRZbR4sZO5PuzsAj6Q2no2dD/Au3s9D61GBnpZQjayyHR1GlWVhYoQMvIyMCRI0cwbdo0ebSNpkzpwslWPSoqSt6k++DkDT/ffN3QW9t4yU9Pg2MWyjoXCHHt5tXYc98q7P27DrqaA9jyUhqEFAbiopftgGtWrxY4Y6gQGAydi4yMlKdLSdsOHDiAgwcP4tatW6itrZUvVANhEwydCwukQ95sHe8FoXvf1v73HhQuqoDyhbUonAI88nYJcpUVyFu4Hc3QIP+tfCSbtiNPo4bmrSq4fcVkYkvVFmS2lGD+d2nq9Du4f0URqurcWnvP9OorA3kvqYCP81C4z+YmDctfewQmkwk5z+d4FZ49C7v7lrkcu1X52H2uFLlysPcIVv7uEeDMOvxI8x3kfZGPtS+g5zUlB/kPAjX/mgd6slbzVD5moga/fmGdeO8xo63m5mbUvPMjqMWUqZS4GBXTVqL0DRqZpNLAUmpqKqqrq8EjboFxGwrWnZ2dXrsREREOSZK82ngq3L9/P+gK8+LFi/jNb34DErCf/vSnUCgUeOedd+RH58+dO4eamhr88Y9/xB133IEZM2Z4cuc2f1piitt8W+bV1hu2zSG5DmWdC+QD0czNQ9qxVaBbPCRJks9JSf41gEC89NiyZvWwCIWtwdA5miY9fPgwvvnmGznRrALdIkIzEKR/gXAPhs71P3jLLrXf60ZX5rZU+lwOSo1dMG7LtAY+Kut+16e5EGESVNlbxBSgAbpGIwzviABHTE2WdnWhS9jD8TUtH3t1wk+juIJrNKJLtxu5qWSQCWd7DVae7kLX6ZXQULF4d94XmR59KZG51QBjowEldLO/MO1ZcjA/28M1o5tjN/x9C3Km9NhrXjmKrpviOA1G6CrysXKbSx//boRBdxQr6WGLKStx0ihsq1YiTXQgk2y7SgUZQDVrZQ8H4aurZm33AwuZLhwAuZ6dg3DkstTV1XHg5sJkEHcDatqXqNEUZ0AOu43pe3v+/Hk5QKM/lHTPx5/+9CdkZ2dDkiTQPXCHDh3C1KlTQT/ZQFejmzdvhkaj6fbg3yoxOs6rYZOxxWv5oBW6+a4Ts1DSudJsR/ouuiO0q1rot/V+ZxMq3lkL0+sHoNPprOn0Wjyir8C6ci3gZEs+NVbtdtV+KupOdaxZ3SRCYzUYOjeQZIOhc/0P3vpzxEoVkscp/fKgHJfst60vh558KcepoIwQtc9Xouj385G+ogqan6+GdRRN5Pd1iRHHqfJ0nEqokkW76H4pvdkCct89+ur2wasRS6DTx5RpWJjUp2OXJAn0dBX9ntu3334LWtO+JFn9PfTQQ/KIm8FgAJXTH+W5c+cG3FbC6DFe6xjabnotH5aF9J0ep/Sr6/L3209bXw49+bptOmfv0ClUfNgMg74ZQtyQLPQNNSfFbIIK6TPUdiveYAKeCAyWzjn2h/6LykUxC2G7D86xzNd2MHSuJ3jz1ZsQKtd+tg5r3q2B5s29OPl236YmQwgXH2oQCURFKTBhQqLHRP+Kqj/dofs+6CdCaO3Oj0qlApXT/XHuyn3lfT9lKv73Z1s9prKFb/pyweUDROD26dwjWFMhZkDK50MdJYmR2yhofqFH/p4abJmrHKDes5uRTGCwda6/bIOhcxy8ufmUNEv3QnepGgfezoQqwo0BZzEBJsAEhjmBgdY5Rxyq2Wtx0tBlv6XGeO4A1j6V7GjC20yACfSDQFg/6nJVJsAEmAATYAJMgAkwgSAT4OAtyMC5udtNgP0zASbABJgAExjZBDh4G9mfLx8dE2ACTIAJMAEm4C+BYWLXK3ijx9+HSd+5m0yACYQwgf5oVX/qhjByPnQmwASCTMCTVjkFb/QDnxZLR5C7xs0xASbABAInQFpFmhVoTapDdQOtF2R7bo4JMAEmANIq0ixXFE7B26hRkTCb211teJ8JMAEmMOQIkFaRZgXaMapDdQOtx/ZMgAkwgWATIK0izXJt1yl4Gz1aidbWNvnxbldD3g9RAnzYTGAIEqCpBNIq0qxAu0d1qC75CLQu2zMBJsAEgkWANIq0ijTLtU2n4I2iO4ViFK5fb5vjhb0AAAGiSURBVHG1430mwASYwJAhQBpFWkWaFWinqA7VJR+B1mV7JsAEAiPA1n0nQBpFWkWa5erFKXijQpVqDDo6OtHcfJNH4AgIJybABIYMAboSJW0ijSKt6mvHqC75IF/ks69+uB4TYAJMYKAJkCaRNpFGkVa5898reCOjsWOt/zy6oaEJLS1GtLdbOJAjMJyYABMIOgESMtIg0iLSJOqATaNo27/U28rmg3ySb2qD2uptyTlMgAkwgdtLgLSHNIi0iDSJWrNpFG27JrfBGxlRtBcfHwuLxQKD4QZ0uqu4cqWREzPgc4DPgaCeA6Q9pEGkRaRJpE2kUQORyBf5JN/UBrXFOsc6z+cAnwPBPgdIe0iDSItIk0ibvGmcx+CNKtE8KzlISkrw+I+wvf2TbC5L7MWNmTATPgcCPwdIg0iLSJNImwYykU/yTW3wZxP4Z8PMmBmfAwNzDpAGkRaRJvnSOK/Bm6/KXM4EmAATYAJMgAkEjQA3xARkAhy8yRj4jQkwASbABJgAE2ACw4MAB2/D43PiXjKBoUWAe8MEmAATYAKDRuD/AAAA//9bFwlaAAAABklEQVQDANkHaRvWK5L6AAAAAElFTkSuQmCC" width="623" height="63" alt="IPHA's Sentiment Meter and Message Volume as of 6:25 a.m. ET on Nov. 10, 2025 | Source: Stocktwits"><figcaption>IPHA's Sentiment Meter and Message Volume as of 6:25 a.m. ET on Nov. 10, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user recommended buying the stock under $3.<stembedurl>https://stocktwits.com/Iiii1ii/message/635561240</stembedurl>Another cheered the news as significant and positive.<stembedurl>https://stocktwits.com/StockNews_Live/message/635557846</stembedurl>IPHA stock is down by 4% this year and over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/us-lawmakers-reportedly-urge-ceo-to-end-union-busting-practices/cLPcLtxREcz">Starbucks Faces Political Heat: US Lawmakers Reportedly Urge CEO To End 'Union Busting’ Practices</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

IPHA Stock Soars Pre-Market After FDA Clears Late-Stage Trial For Lacutamab In Rare Skin Cancers

Shares of Innate Pharma SA (IPHA) soared 13% in the premarket session on Monday after the company said that the U.S. Food and Drug Administration had cleared a confirmatory late-stage trial of Lacutamab in cutaneous T-cell lymphomas to proceed.

Equity

The company now intends to initiate the confirmatory trial in the first half of 2026.


Shares of Caribou Biosciences, Inc. (CRBU) jumped 52% in the pre-market session on Monday after the company announced positive data from early-stage trials of two of its CAR-T cell therapies.While one of the therapies was evaluated for the treatment of multiple myeloma, a blood cancer of plasma cells, the other was assessed in B-cell non-Hodgkin lymphoma (NHL), a cancer that originates in B lymphocytes, a type of white blood cell that fights infection.<h2 class="st-heading-2">Study In Multiple Myeloma</h2>The company said that the first clinical data for its CB-011 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/03/3179047/0/en/Caribou-Biosciences-Announces-Positive-Data-from-CaMMouflage-Phase-1-Trial-of-CB-011-in-Multiple-Myeloma.html">highlights</a> its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma.The company now expects to advance the program into the dose expansion phase by the end of the year. In the dose escalation portion of the trial, CB-011 had a manageable safety profile across all dose levels, the company noted. The portion of the trial evaluated the safety and efficacy of CB-011 in 48 patients at multiple dose levels and following two different chemotherapy treatments.<h2 class="st-heading-2">Study In B-cell non-Hodgkin lymphoma</h2>Meanwhile, data from an early-stage trial of vispacabtagene regedleucel (Vispa-cel) demonstrated the efficacy and durability of the cell therapy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/03/3179104/0/en/Caribou-Biosciences-Announces-Positive-Data-from-ANTLER-Phase-1-Trial-Demonstrating-Efficacy-and-Durability-of-Vispa-cel-CB-010-an-Allogeneic-CAR-T-Cell-Therapy-on-Par-with-Autolog.html">said</a>. Vispa-cel was generally well-tolerated, allowing for administration in the outpatient setting, the company added.“We believe that with these results, Caribou has achieved what the field has long sought — strong evidence that an allogeneic CAR-T cell therapy can be on par with the efficacy and durability of autologous treatments and broaden access with a safety profile that allows for outpatient use,” said CEO Rachel Haurwitz.Allogeneic CAR-T cell therapy is a type of "off-the-shelf" cancer treatment that uses T-cells from a healthy donor, rather than the patient's own cells, allowing immediate availability. Autologous therapy, however, uses a patient's own cells or tissues, which are collected, processed outside the body, and then reintroduced to the same individual.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CRBU">CRBU stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.CRBU stock is up 52% this year and approximately 3% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-sales-in-us-rise-1.6-percent-in-october/cL2NX8OR3CR">Ford Sales In US Rise 1.6% In October On Continued Truck Demand</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For  Cancer Treatments

The company announced positive data from trials of CB-011 and Vispa-cel in relapsed or refractory multiple myeloma and B-cell non-Hodgkin lymphoma, respectively. 

Vor Bio (VOR) announced on Wednesday that its collaborator, RemeGen Co., achieved the primary goal in a late-stage study in China evaluating Telitacicept in adults with primary Sjögren's disease.Shares of <a href="https://stocktwits.com/symbol/VOR">VOR</a> jumped 19% in morning trade at the time of writing. On Stocktwits, retail sentiment around Vor Bio jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘extremely low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:628/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_13_at_10_23_25_AM_png_ff26de0d0d.webp" alt="VOR's Sentiment Meter and Message Volume as of 10:23 a.m. ET on Aug. 13, 2025 | Source: Stocktwits" width="628" height="64"><figcaption>VOR's Sentiment Meter and Message Volume as of 10:23 a.m. ET on Aug. 13, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about Vor, highlighting its ongoing trials and funding availability.<stembedurl>https://stocktwits.com/StockGuru95/message/624945818</stembedurl>Another said they are eyeing a breakout for the stock.<stembedurl>https://stocktwits.com/StockGuru95/message/624929413</stembedurl>The late-stage clinical study in China achieved the primary endpoint of improving disease activity measured by a reduction in EULAR Sjögren's syndrome disease activity index (ESSDAI), compared to placebo, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.vorbio.com/news-releases/news-release-details/telitacicept-achieved-primary-endpoint-phase-3-clinical-study">said</a>. Telitacicept also demonstrated a favorable safety profile in the study, it added.RemeGen now plans to submit a Biologics License Application (BLA) to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China for primary Sjögren’s disease. If approved, primary Sjögren’s disease will become Telitacicept’s fourth approved indication in China after systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG), Vor Bio noted.Sjögren’s disease is a chronic autoimmune condition in which overactive B cells drive inflammation, damaging moisture-producing glands and, in many cases, other organs. Symptoms include dry eyes and dry mouth, alongside fatigue, pain, and systemic complications affecting the skin, lungs, kidneys, and nervous system.“Sjögren’s represents a significant global expansion opportunity for Vor beyond myasthenia gravis, further extending the reach and impact of our portfolio,” said Vor Bio CEO Jean-Paul Kress.Vor Bio and Remegen entered into an exclusive license agreement granting Vor Bio the global rights to develop and commercialize Telitacicept, excluding China, Hong Kong, Macau, and Taiwan, in June. On Wednesday, the company said that it is evaluating the timing of a global late-stage study of the drug in primary Sjögren's disease.VOR stock is up by 78% this year and by 138% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/virtuals-turns-agents-into-a-team/chrCLP7Rd9L">Virtuals Turns Agents Into A Team</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Vor Bio Stock Jumped 19% Today And Retail Investors Are Eyeing A Breakout Rally: Here’s What’s Happening

A late-stage clinical study in China conducted by Vor Bio’s collaborator RemeGen Co., which is evaluating Telitacicept in adults with primary Sjögren's disease, achieved the primary endpoint of improving disease activity compared to placebo.

CNCR
Exchange Traded Concepts Trust - ETCT Loncar Cancer Immunotherapy ETF

Feed

News

Sentiment

Fundamentals

Info

Latest CNCR News

CNCRExchange Traded Concepts Trust - ETCT Loncar Cancer Immunotherapy ETF